Physicians' Academy for Cardiovascular Education

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 in Melbourne, Australia - Prof. David Cherney - Toronto, ON, Canada

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019

Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease

3' education - Apr. 17, 2019 - Melbourne, Australia

Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD

3' education - Apr. 15, 2019 - Melbourne, Australia

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia

Detection of AF with wearable technology to prevent stroke

3' education - Apr. 8, 2019

Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation

3' education - Apr. 8, 2019

Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF

3' education - Apr. 8, 2019

No difference in survival with immediate vs. delayed coronary angiography after cardiac arrest in NSTEMI patients

3' education - Apr. 8, 2019 - Jorrit Lemkes

Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction

3' education - Apr. 8, 2019 - Dr. Eri Kato, Kyoto, Japan

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh

Device safely keeps HF patients out of the hospital

3' education - Mar. 17, 2019

Long-term data confirm safety and efficacy of oral antibiotics in left-sided endocarditis

3' education - Mar. 27, 2019

TAVR vs surgery in aortic stenosis: reason for a paradigm flip?

3' education - Mar. 19, 2019 - New Orleans, LA, USA - Janet Wyman

Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events

3' education - Mar. 19, 2019 - Deepak L. Bhatt, MD

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD

Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk

3' education - Mar. 19, 2019 - Anne Carol Goldberg, MD

Substantial reduction in clinical outcomes with TAVR in aortic stenosis patients at low surgical risk

3' education - Mar. 19, 2019 - New Orleans, LA, USA - Martin B. Leon, MD

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Proof-of-concept study shows 84% true AF in those with irregular pulse detected with smartwatch

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD

Benefits of dual COMPASS regimen also seen in patients with moderate renal dysfunction

Literature - May 21, 2019 - Fox KAA et al., - J Am Coll Cardiol. 2019

An analysis of the COMPASS trial in patients with GFR ≥60 or <60 mL/min showed consistent treatment benefit of the combination of rivaroxaban 2.5 mg bd plus aspirin, vs aspirin alone.

Twice yearly administration of PCSK9 siRNA yields persistent LDL-c lowering

News - May 21, 2019

New data of the ORION-3 trial demonstrate that twice a year dosing of the siRNA directed at PCSK9 mRNA inclisiran gives sustained and safe lowering of LDL-C by more than 50 percent for up to 3 years, on top of LDL-c lowering therapies.

Estimating individual absolute risk reductions and increases of DOAC treatment in AF patients

Literature - May 21, 2019 - Stam-Slob MC et al. - Circulation. 2019

A prediction model was developed based on RE-LY data, to assess the absolute treatment benefit and harm from dabigatran therapy in individuals with AF with readily available patient characteristics

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 in Melbourne, Australia - Prof. David Cherney - Toronto, ON, Canada
Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

Homozygous FH in children is clinically more diverse than clinical diagnostic criteria suggest

Literature - May 20, 2019 - Luirink IK et al., - J Clin Lipidol. 2019

LDL-c levels vary greatly among pediatric patients with genetically defined hoFH, and overlap exists between the LDL-c levels and phenotypes of severe heFH and hoFH.

Intensive BP lowering also seems beneficial in adults with diabetes, irrespective of baseline BP

Literature - May 20, 2019 - Rahman F et al. - Hypertension. 2019
An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.

An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.

Manipulation of language in reporting of nonsignificant results for primary outcomes in CV RCTs

Literature - May 15, 2019 - Khan MS, et al. - JAMA Netw Open 2019

Spin, defined as manipulation of language to potentially mislead readers, was identified in 57% of abstracts and 67% of main texts in CV RCTs that reported statistically non-significant results for primary outcomes.

Increase in hs-troponin I associated with higher risk of CVD in individuals without CVD history

Literature - May 14, 2019 - Jia X, et al. - Circulation 2019

In individuals without CVD history in the ARIC study, increase in troponin I, measured by a high sensitivity assay, was associated with ASCVD, global CVD, CHD, stroke, HF hospitalization, and all-cause mortality.

Brain aminopeptidase A inhibitor reduces blood pressure in a high-risk diverse population

Literature - May 13, 2019 - Ferdinand KC et al. - Circulation 2019

First-in-class firibastat, a selective and specific inhibitor of brain aminopeptidase A, safely reduced BP in hypertensive, overweight patients of multiple ethnic origins.

FDA approves new treatments for transthyretin-mediated amyloidosis-cardiomyopathy

News - May 13, 2019

Tafamidis meglumine and tafamidis capsules have received FDA approval for treatment of cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM) in adults.

Estimation of required reduction of Lp(a) for a clinically relevant reduction of CHD risk

Literature - May 13, 2019 - Lamina C et al. - JAMA Cardiol. 2019

A mendelian randomization analysis in population-based cohorts assessed that lowering Lp(a) by 65.7 mg/dL yields a similar CHD event risk reduction as lowering LDL-c by 38.67 mg/dL

Total antibiotic exposure time in different life-stages associated with higher CVD risk in later life

Literature - May 9, 2019 - Heianza Y et al. - Eur Heart J 2019
In women, longer total exposure to antibiotics in middle- and late adulthood was significantly associated with risk of CVD in later life, and antibiotic use in middle adulthood with risk of CHD but not of stroke.

In women, longer total exposure to antibiotics in middle- and late adulthood was significantly associated with risk of CVD in later life, and antibiotic use in middle adulthood with risk of CHD but not of stroke.